Clinical Trial

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2027-11 -> 2027-02 2026-07-19
Trial Details
NCT Number NCT06413706
Lead Sponsor Eli Lilly and Company
Conditions Glioma
Enrollment 45 participants
Start Date 2024-10-25
Primary Completion 2027-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-17